Inicio › Cáncer de ovario › Colorado › Denver
Ensayos clínicos de Cáncer de ovario en Denver, CO
16 estudios para Cáncer de ovario buscan participantes en centros de Denver y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
The Vanguard Study: Testing a New Way to Screen for Cancer
ReclutandoSe aceptan voluntarios sanos
- Kaiser Permanente-Franklin, Denver
A Study of PHST001 in Advanced Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute at HealthOne, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- Rocky Mountain Cancer Center, Denver
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
ReclutandoFase 1
- SCRI at HealthOne, Denver
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
ReclutandoFase 1
- Sarah Cannon Research Institute at HealthONE /ID# 278785, Denver
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
ReclutandoFase 3
- AdventHealth Medical Group - Porter, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
ReclutandoFase 1/2
- SCRI at HCA Health One, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
ReclutandoFase 1
- Sarah Cannon Research Institute - Denver DDU, Denver
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
ReclutandoFase 1
- Normunity Investigational Site, Denver
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
ReclutandoFase 3
- Cancer Center of Colorado at Sloan's Lake, Denver
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
ReclutandoFase 1/2
- Research Site, Denver
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute at HealthONE, Denver
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
ReclutandoFase 1
- Dren Investigational Site, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Denver
Más información sobre Cáncer de ovario en MedlinePlus
Ensayos de Cáncer de ovario en otras ciudades
- Houston, TX89 estudios
- New York City, NY69 estudios
- Boston, MA61 estudios
- Los Angeles, CA50 estudios
- Nashville, TN49 estudios
- Arlington, VA46 estudios
- Philadelphia, PA44 estudios
- Columbus, OH39 estudios
- St. Louis, MO38 estudios
- Chicago, IL36 estudios
- San Antonio, TX31 estudios
- Cleveland, OH30 estudios
Otros estudios en Denver
- Cáncer metastásico29 estudios
- Cáncer de seno29 estudios
- Cáncer de pulmón de células no pequeñas27 estudios
- Mieloma múltiple27 estudios
- Cáncer del colon y del recto23 estudios
- Melanoma19 estudios
- Cáncer de próstata19 estudios
- Cáncer (todos los tipos)18 estudios
- Cáncer de pulmón16 estudios
- Cáncer de endometrio15 estudios
- Linfoma no Hodgkin14 estudios
- Cáncer de páncreas13 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.